| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/2009 | EP2081938A2 Substituted 8-piperidinyl-2-pyridinyl-pyrimido ý1,2-a¨pirimidin-6-one and 8-piperidinyl-2-pyrimidi nyl-pyrimidoý1,2,-a¨pyrimidin-6-one derivatives |
| 07/29/2009 | EP2081937A2 Triazolopyridazine protein kinase modulators |
| 07/29/2009 | EP2081936A2 Pyrrolotriazine kinase inhibitors |
| 07/29/2009 | EP2081935A1 Polymorph b of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-n-methyl-acetamide |
| 07/29/2009 | EP2081932A2 2-o'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor |
| 07/29/2009 | EP2081931A2 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
| 07/29/2009 | EP2081928A2 Pyrrolo-pyridine kinase inhibitors |
| 07/29/2009 | EP2081927A1 Piperidine derivatives as renin inhibitors |
| 07/29/2009 | EP2081926A1 Preparation and purification of mupirocin calcium |
| 07/29/2009 | EP2081923A1 Certain substituted amides, method of making, and method of use thereof |
| 07/29/2009 | EP2081921A1 Short-acting benzodiazepine salts and their polymorphic forms |
| 07/29/2009 | EP2081918A2 Mitotic kinesin inhibitors and methods of use thereof |
| 07/29/2009 | EP2081917A2 Cytochrome p450 oxidase inhibitors and uses thereof |
| 07/29/2009 | EP2081916A1 Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties |
| 07/29/2009 | EP2081915A2 Bicyclic heteroaromatic compounds |
| 07/29/2009 | EP2081910A1 Novel compounds |
| 07/29/2009 | EP2081909A1 Process for the sulfinylation of a pyrazole derivative |
| 07/29/2009 | EP2081908A1 Process for the sulfinylation of a pyrazole derivative |
| 07/29/2009 | EP2081907A1 Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders |
| 07/29/2009 | EP2081906A1 Sitamaquine tosylate for the treatment of leishmaniasis |
| 07/29/2009 | EP2081904A1 Aripiprazole hemifumarate and process for its preparation |
| 07/29/2009 | EP2081902A1 Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
| 07/29/2009 | EP2081901A1 Novel 2-amino-pyridine derivatives and their use as potassium channel modulators |
| 07/29/2009 | EP2081898A2 Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
| 07/29/2009 | EP2081897A1 Isoindol derivatives as ep4 receptor agonists |
| 07/29/2009 | EP2081896A1 Benzoisoindole derivatives and their use as ep4 receptor agonists |
| 07/29/2009 | EP2081895A1 Hydrobenzamide derivatives as inhibitors of hsp90 |
| 07/29/2009 | EP2081894A1 1h-indole-2-carboxylic acid derivatives useful as ppar modulators |
| 07/29/2009 | EP2081892A1 Compounds and methods for treating protein folding disorders |
| 07/29/2009 | EP2081891A2 Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
| 07/29/2009 | EP2081890A1 Arylsulfonyl pyrrolidines as 5-ht6 inhibitors |
| 07/29/2009 | EP2081889A1 Sulfonamide derivatives |
| 07/29/2009 | EP2081888A1 N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| 07/29/2009 | EP2081648A2 Carbamate compounds for use in treating depression |
| 07/29/2009 | EP2081647A2 Method of preventing or treating metabolic syndrome |
| 07/29/2009 | EP2081600A1 Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| 07/29/2009 | EP2081598A2 Bioavailable combinations for hcv treatment |
| 07/29/2009 | EP2081595A2 Combination treatment of cd38-expressing tumors |
| 07/29/2009 | EP2081590A2 Cancer stem cell-targeted cancer therapy |
| 07/29/2009 | EP2081583A2 Triglyceridic nature oil with improved nutritional properties and process for the preparation thereof |
| 07/29/2009 | EP2081580A1 Polyethylene glycol-g-csf conjugate |
| 07/29/2009 | EP2081579A2 Food supplement agent based on rock |
| 07/29/2009 | EP2081578A1 Combination of a glucocorticoid and a beta-cyclodextrin conjugated vitamin a derivate complex |
| 07/29/2009 | EP2081577A1 Prostaglandin e2 (pge2) as an adjuvant in monoclonal antibody generation |
| 07/29/2009 | EP2081576A2 Method of improving bioavailability for non-sedating barbiturates |
| 07/29/2009 | EP2081574A1 Buprenorphine-containing non-pressurised spray composition for transmucosal administration |
| 07/29/2009 | EP2081573A2 Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections |
| 07/29/2009 | EP2081572A1 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| 07/29/2009 | EP2081571A1 MIXED ORL 1/µ AGONISTS FOR TREATING PAIN |
| 07/29/2009 | EP2081570A2 Anti-resorptive and bone building dietary supplements and methods of use |
| 07/29/2009 | EP2081569A2 Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| 07/29/2009 | EP2081568A1 Compositions containing zinc salts for coating medical articles |
| 07/29/2009 | EP2081567A1 Cosmetic product for the treatment of cicatricial tissues |
| 07/29/2009 | EP2081566A1 Improved biological effects of compositions comprising rosmarinic acid |
| 07/29/2009 | EP2081565A2 Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
| 07/29/2009 | EP2081564A2 Use of citrulline for treating undernutrition conditions |
| 07/29/2009 | EP2081563A1 Pharmaceutical formulations |
| 07/29/2009 | EP2081562A2 Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
| 07/29/2009 | EP2081561A2 Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| 07/29/2009 | EP2081560A1 Treatment of gastrointestinal diseases |
| 07/29/2009 | EP2081556A1 Stable imatinib compositions |
| 07/29/2009 | EP2081550A2 Coating capsules with active pharmaceutical ingredients |
| 07/29/2009 | EP2081549A2 Ophthalmic compositions containing diglycine |
| 07/29/2009 | EP2081546A2 Multiple unit tablet compositions of benzimidazole compounds |
| 07/29/2009 | EP2081450A1 Long-term feed - cancer patient |
| 07/29/2009 | EP2081434A2 Triazolopyrimidine derivatives as adp p2y12 receptor antagonists |
| 07/29/2009 | EP2081433A2 Triazolopyrimidine derivatives as adp p2y12 receptor antagonists |
| 07/29/2009 | EP2081431A1 Organic compounds |
| 07/29/2009 | EP2081430A2 Salt forms of substituted benzothienyl compounds |
| 07/29/2009 | EP2006271A9 Substituted bicyclic cyclic derivative and use thereof |
| 07/29/2009 | EP2005951A9 Agent for improving nervous system cell functions |
| 07/29/2009 | EP1989200B1 [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases |
| 07/29/2009 | EP1979321B1 Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |
| 07/29/2009 | EP1933829B1 Method of combating infection |
| 07/29/2009 | EP1931679A4 Analogs of salinosporamide a |
| 07/29/2009 | EP1926712B1 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 07/29/2009 | EP1909790A4 Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
| 07/29/2009 | EP1883390B1 Topical compositions |
| 07/29/2009 | EP1855693B1 Azithromycin powder for oral suspension compositions |
| 07/29/2009 | EP1841734B1 5-aminoindole derivatives |
| 07/29/2009 | EP1807407B1 Aromatic amides as inhibitors of c-fms kinase |
| 07/29/2009 | EP1786807B1 Heterocyclic antiviral compounds |
| 07/29/2009 | EP1773339A4 Crystalline form of donepezil hydrochloride |
| 07/29/2009 | EP1771177A4 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| 07/29/2009 | EP1748982B1 (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease |
| 07/29/2009 | EP1737474A4 Non-gmo metal amino acid chelates and non-gmo metal amino acid chelate-containing compositions |
| 07/29/2009 | EP1732917B1 Selected cgrp antagonists, methods for the production thereof and their use as medicaments |
| 07/29/2009 | EP1727550B1 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein |
| 07/29/2009 | EP1713809B1 Dimeric azacyclic compounds and their use |
| 07/29/2009 | EP1711170B1 Transdermal delivery device for dihydropyridine type calcium antagonists containing two fatty acids |
| 07/29/2009 | EP1692250B1 Adhesion inhibition of micro organisms by non-ionic surfactants |
| 07/29/2009 | EP1686119B1 Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors |
| 07/29/2009 | EP1682127B1 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| 07/29/2009 | EP1678166B1 Protein kinase inhibitors |
| 07/29/2009 | EP1664057B1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases |
| 07/29/2009 | EP1653955A4 Hydroxylamine substituted imidazo-containing compounds |
| 07/29/2009 | EP1641791B1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| 07/29/2009 | EP1638968B1 Hexahydropyridoisoqinolines as dpp-iv inhibitors |
| 07/29/2009 | EP1628667B1 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
| 07/29/2009 | EP1628663B1 Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |